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Abstract
Hepatocellular  carcinoma  (HCC)  is  a  major  worldwide  health  problem,  which  is
expected  to  increase  steadily  due  to  different  underlying  liver  diseases.  Surgical
treatment modalities including liver transplantation (LT) or liver resection (LR) are the
mainstay options for early cases of HCC. Liver transplantation for well‐selected cases
provides excellent survival outcomes comparable to nonmalignant indications of LT.
Living donor liver transplantation (LDLT) is an alternative option or even the sole one
in the current  era of  organ shortage problem and in some Asian countries  where
deceased organ donation is markedly reduced due to various reasons. The adoption of
LDLT for HCC treatment elicited many dynamic changes and debates to the dilemma
of LT as a whole. In this chapter, we focus on different perspectives of LDLT for HCC,
including  selection  criteria  evolution,  controversial  topics,  ethical  considerations,
operative highlights, and other points.
Keywords: hepatocellular carcinoma, living donor, liver, transplantation, criteria, lo‐
co‐regional therapy
1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause
of deaths globally. The selection of treatment modalities for HCC is challenging because it
depends not  only  on the  stage  of  tumor and the  patient's  performance but  also  on the
underlying  liver  function.  Though the  staging  systems  of  HCC are  clinically  useful  for
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treatment allocation,  the decision making should be tailored to each patient,  taking into
account morphological, pathological, and biological tumor criteria. Liver resection (LR) or liver
transplantation (LT) can be adopted as a surgical curative therapy for early disease. Ablative
therapies such as radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) can
also cure small tumors. Transarterial chemoembolization (TACE), transarterial radio emboli‐
zation (TARE), and external beam radiation therapy (EBRT) can control locally advanced
disease that is no longer amenable to cure [1].
Liver transplantation has been considered theoretically the best treatment for HCC since it
cures the cancer and its underlying pathology. Milan criteria (MC) were the cornerstone for LT
because patient selection according to them resulted in survival outcome comparable to LT for
nonmalignant cases. More cases of HCC were subjected to LT with the changes made in 2002
in western countries when additional points were added to the model for end‐stage liver
disease (MELD) scoring system for HCC patients that are within MC. However, the protracted
waiting list for deceased donor liver transplantation (DDLT) took many patients beyond MC
and hence lost their chance of LT [2].
The incorporation of living donor liver transplantation (LDLT) into the treatment roadmaps
of HCC not only gave a new horizon to more patients, but also elicited many dynamic scientific
debates and opened different perspectives for the field of LT in general and the treatment of
HCC in particular. Thanks to the extensive research and experience of many groups working
on LDLT, especially the Asian transplantation groups, most LT centers now are achieving
excellent results.
Specifically to the treatment of HCC, LDLT has several major advantages including: avoidance
of prolonged waiting times, allowing elective timing of transplantation under best circum‐
stances both for the patient and the tumor burden, not consuming the public donor pool that
may reduce the chance of LT for nonmalignant cases awaiting transplant, and providing organ
replacement therapy in parts of the world where brain death and deceased donation are less
commonly accepted [3].
In addition to the conventional hepatitis virus‐related HCC, a steadily increasing burden of
HCC will be witnessed with the emergence of alcohol‐related cirrhosis and nonalcoholic
steatohepatitis (NASH) as potential major causes of HCC, adding more burden to the trans‐
plantation demands and worsening the worldwide problem of organ shortage. It has been
recognized that fine‐tuning and timing of liver transplantation for HCC are only possible with
live organ donation. For these reasons, the need for implementation and optimization of LDLT
program will continue in the near future [4–6].
In the following sections, we will discuss basic concepts, criteria evolution, ethical considera‐
tions, and controversial topics regarding LDLT for HCC treatment, some of them are com‐
monplace among LDLT and DDLT. The technical details of the procedure of LDLT in general
are beyond the scope of this chapter. However, surgical details that are related to the oncologic
outcome of the patients with HCC are highlighted.
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2. Current practice of LDLT for HCC
HCC represents more than 90% of primary liver cancers and It has a well‐remarked geographic
distribution. Around 85% of cases occur in East Asia, sub‐Saharan Africa, and Melanesia. The
great burden of HCC is most prevalent among the less developed world. In developed regions,
the incidence is low, except for Southern Europe where the incidence is significantly higher [7,
8].
By and large, LDLT has emerged as an alternative to DDLT and it is the only option for patients
with HCC in many Asian countries, where the problem of organ shortage is commonly faced.
It also provides a suitable option for patients exceeding the MC in western countries such as
the United States and Europe, and in the absence of legislative regulations and setup for DDLT
in some developing countries especially in the Middle East and North Africa [9–11].
At the beginning of this century, it was estimated that LDLT would represent a significant
proportion of the patients transplanted with HCC. Unfortunately, the risks of death and major
complications for the healthy donors at the early experience (0.3 and 2%, respectively) reduced
its practice on a wide scale. With the cumulative experiences over the past two decades, LDLT
is now practiced smoothly in centers of excellence with experience of hepatobiliary surgery
and transplantation medicine [7, 12].
2.1. Western experience
Since 2002, HCC patients who are within Milan criteria gain additional points under the MELD
organ allocation policy. This resulted in shorter waiting time for HCC patients in many regions
of the United States, obviating the need for LDLT. In some regions, however, longer waiting
times with higher dropout rates support the use of LDLT for cases of HCC within the Milan
criteria and in candidates who do not meet criteria for waiting list priority [13].
The situation of LDLT within the western experience can be configured from the 2012 release
of European Association of Study of the Liver (EASL) guidelines, that mentioned “Living
donor liver transplantation is an alternative option in patients with a waiting list exceeding 6–
7 months, and offers a suitable setting to explore extended indications within research
programs” [7].
In the United States, approximately 7000 new patients with HCC are put on the waiting list
for LT every year, 10–15% of whom die during the waiting period. In Europe and the United
States, the dropout rate at various centers ranges between 15 and 35%. From this perspective,
LDLT offer a survival advantage to a significant proportion of HCC patients in the western
world [14].
2.2. Eastern experience
The liver transplantation setup in Asia differs from that in the West, in the fact that no priority
is given to HCC patients. This setup is formulated to avoid the inevitable shift of most of the
deceased grafts to the persistently increasing HCC cases on the expense of nonmalignant cases
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waiting LT. The resultant wait‐list lead Asian centers to practice various approaches to cover
the needs, including bridging treatment for HCC, salvage transplantation after prior hepatec‐
tomy and LDLT for HCC. Shortage of donors in Asian countries is attributed to many factors
including cultural and religious beliefs [10, 15].
3. Basic concepts
3.1. Philosophy
The most prominent advantage of LDLT for HCC treatment is the reduction of waiting time
on the list for all cases including other etiologies of liver failure with nearly no effect on public
donor pool. Living donor liver grafts are dedicated gifts to the recipients and are generally of
good quality taking into account that most of living donors are healthy young individuals [15,
16].
The concept of “gifting” allowed LDLT for HCC patients who are beyond MC or any other
proposed criteria and opened the door for liberal expansion. This concept is not accepted in
the wait list of DDLT in which the procedure is conditioned to the “within criteria” cases only.
The concept of “gifting” must not be taken for granted in the case of LDLT. Since the risk of a
living donor is taken, selection criteria must be adopted for HCC patients with optimization
of the pretransplantation conditions to ensure a high survival outcome. In other words, the
readily available willing donor does not justify the ultramajor procedure of transplantation in
the absence of a survival benefit for the recipient. In addition, donor safety remains the other
pillar of a sound decision of LDLT [17].
3.2. Indications
LDLT is indicated in HCC patients, who are within accepted universal or regional criteria for
transplantation. In view of organ scarcity, the indications can be described currently to be
result‐oriented in terms of overall and recurrence‐free survival. Consequently, there is marked
variation between different regions and institutions for applied indications. In essence, cases
fitting Milan criteria are indicated for LDLT if waiting list would be >7 months or if there is a
willing available donor. Milan criteria form the solid base of morphological indications for
HCC. As discussed later, LDLT has allowed transplantation for patients who are outside Milan
criteria according to the dynamically changing criteria in different institutions [18, 19].
3.3. Contraindications
Likewise, there is heterogeneity in the contraindications between different regions according
to criteria limits for patient selection. However, there is a body of evidence that LDLT is
absolutely contraindicated in the following conditions: cases of HCC that show major vascular
invasion as evidenced by pretransplant imaging, the presence of extrahepatic metastases
including suspicious porta hepatis nodal disease and cases with ruptured HCC. Absolute
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contraindications of LDLT in nonmalignant cases hold true for HCC and include cases with
uncontrolled systemic infection or lethal uncontrolled medical comorbidities [20].
4. Terminology
With the implementation of LDLT programs and better understanding of the clinical course
and biological nature of HCC, various clinical settings have emerged. In addition, the current
progress of the interventional anticancer therapies enforced the armamentarium of the HCC
management for all clinical scenarios. The following are different settings rather than different
types of LDLT.
4.1. Primary LDLT
It is the procedure of LDLT performed upfront for the treatment of the cancer and underlying
primary liver disease. In this setting, no previous liver resection is performed but initial ablative
loco‐regional therapies like RFA or PEI may have been performed. It is carried out for nonre‐
sectable HCC cases fitting the standard Milan criteria, UCSF criteria or other established and
justified criteria for individual institutions. According to Barcelona Clinic Liver Cancer (BCLC)
guidelines, primary LDLT is conducted for early cases of HCC with poor liver functions that
cannot tolerate initial resection or ablation [7].
4.2. Salvage LDLT
In this setting, LT is performed when there is tumor recurrence or deterioration of liver
functions after initial hepatectomy. The integral point in salvage LDLT is that it is performed
aiming at a similar outcome to nonrecurrent cases. The pretransplant setting in the case of
salvage LT after previous hepatectomy differs from that of primary LT in the availability of
tissue pathology, so that almost all factors that determine tumor's behavior (grade, the presence
or absence of microvascular invasion, the grade of necrosis in response to loco‐regional
therapy) are determined beforehand. That is why the predictive power of outcome of salvage
LT should be more precise. Very importantly, we should consider that patients who have
“within criteria” recurrence after hepatectomy, and hence amenable to salvage LT, are not more
than 25% in some series. This means that nearly 70% of cases may miss the chance of a curative
LT at all. The transplantability at the time of recurrence has been found to be an important
variable determining the final outcome [21]. Noteworthy that when salvage LT is considered
due to transplantable recurrence, the recurrence pattern should be evaluated before embarking
into LT even if the liver functions and tumor burden are amenable to LT. Intrahepatic recurrent
tumors after hepatectomy originates from either primary tumor metastases or de novo tumor
foci. The interval and histopathological analysis of hepatectomy specimens give a clue to the
pattern of recurrence. Tumors recurring in the first 12 months are most likely tumor metastases
within the liver, while those arising after 12 months represent newly developed tumor foci. At
histopathological analysis of hepatectomy, the presence of satellite nodules and portal vein
invasion herald tumor metastases and early recurrence. The transplantation team should not
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rush to salvage LDLT except after considering the biological aggressiveness of the recurrent
tumor and the likelihood of re‐recurrence into the implanted neo‐liver [22].
4.3. Sequential LDLT and preemptive LDLT
They are new categories with no consensus, performed in some centers within institutional
protocols. In preemptive LDLT, cases that underwent initial hepatectomy and showed adverse
histopathological criteria like microvascular invasion or satellite tumor nodules are prepared
for LDLT without unnecessary waiting for the inevitable expected recurrence [21, 23, 24].
In sequential LDLT, pretransplant loco‐regional therapy (LRT) is administered aiming at
complete pathological necrosis of the index tumor before LDLT for cases within accepted
criteria. Moreover, LDLT is performed after a scheduled short interval due to donor availability.
The exact duration of the interval is not yet determined. Some centers perform LDLT after 3
months from the time of pretransplant therapy. This concept developed from the cumulative
experience of histopathological assessment of explanted livers and the impact of pathological
necrosis on post LT outcomes. HCC patients who achieve pathological necrosis ≥60% have
significantly better overall survival and recurrence‐free survival [25].
The employment of salvage LDLT is sometimes controversial. Some transplant surgeons,
in view of certain radiological, pathological and biological hallmarks, don’t prefer to wait
for the inevitable recurrence or deterioration of patient or liver conditions to occur
(preemptive LDLT). Some argue that the readily available donor associated with vigilant
surveillance can always tailor the transplantation in the right time for the best outcome
(salvage LDLT).
5. Evolution of selection criteria
Over the previous two decades, criteria of LT had been expanded and modified from mor‐
phological and nonmorphological perspectives. Nevertheless, Milan criteria (MC) keep their
place as the gold standard for LT. The long‐term outcome and prognostic impact of LT within
MC had been reproducibly studied with consistent excellent results [19, 26].
5.1. Why the criteria for LDLT had been expanded?
The MC advocated by Mazzaferro et al. [27] in 1996 are considered the base upon which several
centers around the world validated their experiences in liver transplantation. These first clear‐
cut criteria were published in the New England journal of medicine as a practice changing and
ground breaking progress in HCC treatment. That is because MC provided posttransplant
survival rates of 75–95% at 2 years and 70–80% at 5 years in several studies. Indeed, a meta‐
analysis of published data has confirmed the survival advantage of MC and its association
with a low risk of selecting patients with aggressive tumors [19, 27–29].
However, Milan criteria have been expanded and modified steadily for the following reasons:
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1. They were considered too restrictive and many reports showed similar outcomes for cases
beyond Milan [13, 30].
2. The growing evidence of the clear contribution of nonmorphological tumor characteristics
to the outcome of patients after transplantation. So, the static “morphological” Milan
criteria were expanded and modified. The other pathological and biological tumor criteria
include: micro‐vascular invasion, alpha‐feto protein (AFP) level, deoxy‐gamma carboxy
prothrombin (dGCP) level and tumor avidity on PET scan [31–35].
3. The observation of two incorrectly estimated groups: an underestimated group that had
been transplanted within MC but showed worse outcome and an overestimated group
that was beyond MC and had comparable outcome after LDLT [35, 36].
5.2. Selection criteria according to different centers of excellence (Table 1) [27, 37–45]
Selection criteria of liver transplantation in different series and centers of excellence
Criteria Parameters Type of parameters Over‐all survival
Milan Solitary tumor ≤ 5 cm[T1], up to 3 tumors non >3 cm, no
macrovascular invasion
Morphological only 85% (4‐year)
UCSF Solitary HCC ≤ 6.5 cm, or ≤ 3 nodules with the largest
lesion ≤ 4.5 cm and a total tumor diameter ≤ 8 cm
Morphological only 75% (5‐year)
Modified Milan
(Up to 7)
Tumor number + size of the largest tumor (cm) ≤ 7 Morphological only 71% (5‐year)
Toronto Any tumor size or number, if pretransplant tumor biopsy
showed no poor differentiation, no major vascular
invasion, no extrahepatic disease
Morphological‐
pathological
72% (5‐year)
Kyoto University ≤ 10 tumors, all ≤ 5 cm and the serum level of des. Gama
carboxy prothrombin (d.GCP) ≤ 400 mIU/ml
Morphological‐
biological
87% (5‐year)
Kyushu
University
HCC ≤ 5 cm and a serum d.GCP ≤ 300 mIU/ml. It had
been refined by adding neutrophil to lymphocyte ratio
(NLR) >4
Morphological‐
biological
83% (5‐year)
Tokyo University 5‐5 rule: HCC not larger than 5 cm and no more than 5
nodules
Morphological only 75% (5‐year)
Asan Medical
Center
HCC not larger than 5 cm, 6 or fewer nodules without
gross vascular invasion
Morphological only 82% (5‐year)
Hangzhou HCC ≥ 8 cm if serum alpha‐fetoprotein level ≤ 400 ng/ml
and only grade I or II
Morphological,
biological, and
pathological
72.% (5‐year)
Table 1. Different selection criteria for liver transplantation adopted in most of transplantation in the world. Note that
the main western criteria (Milan, UCSF, UP to 7) depend largely on morphology. Eastern‐based criteria (Kyoto‐
Kyushu‐Hangzhou) had modified by incorporating biological behavior of the tumors. The Toronto criteria are unique
in its sole dependence on pretransplant biopsy.
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Milan criteria were based on preoperative imaging and validated in many institutions all over
the world [27]. In 2001, Yao et al. in the University of California San Francisco (UCSF) expanded
the morphological criteria based on pathological assessment of explanted livers and then they
prospectively validate their criteria based on pretransplant imaging in 2007 [37, 46]. Though
this set of criteria is applied successfully in many regions, it has not been applied on a wide
scale because they allow transplantation for large HCCs (6.5 cm, representing a tumor volume
of 144 cm3), which had been associated with worse outcomes in some studies. UCSF criteria
(like Milan criteria) also exclude all patients with more than three lesions, some of whom may
have the same outcome as those within criteria [47]. The 3‐ and 5‐year survival rates after LDLT
based on the UCSF criteria range between 78–96% and 66–90%, respectively, in different centers
[28]. This wide variation of survival outcomes may also be attributed to variations of the
surgical outcome and early mortality.
It should be emphasized that there are no consensus criteria for LDLT allocation. Each
individual institution adopts one of the current criteria, tailoring treatment to their unique
patient and general circumstances. Most of centers with high experience in LDLT for HCC
currently focus on modification rather than numerical expansion of the number and size of
tumors. The incorporation of biological factors (tumor markers, inflammatory markers) or
available pathological factors from previous hepatectomy help select best candidates and
hence predict the outcome and protect against recurrence [29, 35, 48].
6. Preoperative evaluation
Liver transplantation under optimal circumstances is a clear benefit of LDLT. The procedure
can be carried out in a timely fashion after exhaustive assessment of tumor burden by different
imaging modalities and biological markers. The tumor burden can then be manipulated by
pretransplant therapies using the different loco‐regional treatment options. Preoperative
evaluation of the donor is not much different from the nonmalignant cases of LDLT except for
some additional ethical perspectives as discussed previously. For the recipient, the details of
preoperative assessment are beyond the scope of this chapter. However, we consider some
important points in the pretransplant setting.
6.1. Imaging
Preoperative imaging of the recipient aims at assessment of tumor burden and suitable
metastatic workup, for occult HCC or other cancer types. Dynamic CT or MRI with arterial
enhancement is the standard of care according to high level of evidence. Extrahepatic staging
should include CT chest and CT or MRI of abdomen and pelvis [12, 23].
The discrepancy between preoperative imaging and real tumor burden in explanted livers had
been investigated in many centers. The state‐of‐the‐art imaging modalities are not 100%
accurate. CTA and MRI were both accurate to determine whether patients fit within the Milan
or UCSF criteria, but CTA was slightly better than MRI to evaluate tumor number and size [49].
In the current era of pretransplant invasive therapies, the liver background became more
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confusing due to the presence of regenerative nodules, necrotized tumors, and other small
tumors [35].
The incidental finding of pulmonary nodule(s) on pretransplant CT warrants appropriate
evaluation. Many studies had determined a cutoff point to the size of pulmonary lesion at
5 mm. A lesion < 5 mm is less likely to be malignant and if remained stable or showed
regression over a period of 3–6 months, liver transplantation is performed. For a lesion > 5
mm, a biopsy is needed to rule out malignant nature that contraindicates transplantation.
If this lesion was the same in repeated images over previous 2 years, the possibility of
infection is most likely and management is done accordingly. Video‐assisted thoracic sur‐
gery (VATS) is perfectly employed for an excision biopsy of these small pulmonary nod‐
ules [50].
6.2. Alpha‐feto protein (AFP)
This biological tumor marker plays important role in the assessment of tumor burden and
aggressiveness although many other markers have been used in clinical practice over the past
two decades. The AFP value has its clinical significance either in the preoperative or the
posttransplant settings. In addition, the dynamic changes to its value in relation to downstag‐
ing therapy had been explored. An important question in the preoperative setting is its role as
an exclusion tool, either alone or in combination of other radiological, biological, or patholog‐
ical markers.
Some studies check the cutoff level above which patients should not undergo LT. At an AFP
level >1000 ng/ml, approximately 5% of patients would be excluded from LT with 20%
reduction in the rate of HCC recurrence. If a lower cut‐off level is applied, this would result in
a greater reduction in the recurrence rate but at the expense of excluding many more patients
from LT who might not have tumor recurrence and would have benefited from LT. Also,
patients who had decline of an initial AFP level >1000 ng/ml after loco‐regional therapy had a
more favorable prognosis after LT. Alpha feto‐protein level <1000 has thus been combined to
the UCSF criteria for patient selection in some centers [51].
More recently, a prospective multicenter study has explored the use of a combination of total
tumor volume (TTV) ≤ 115 cm3 and AFP ≤ 400 ng/ml as an exclusion tool from LT in centers
with a median waiting time of 8 months. This study took an advantage from a previous
observation of the inferior survival outcome of patients who are within MC but have the AFP
level ≥400 ng/ml. In this study, patients who were beyond MC but within TTV/AFP had survival
outcome similar to cases within MC [29].
Many other biomarkers can be evaluated in the pretransplant setting to predict the posttrans‐
plant outcome. A recent study in our center showed that repeated measurement of serum levels
of novel biomarkers including fibroblast growth factor‐2 (FGF‐2), survivin, Ki67, endostatin,
and vascular endothelial growth factor (VEGF), before and after LDLT for HCC, could predict
HCC recurrence [52].
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6.3. Fludro‐deoxy glucose‐positron emission tomography (FDG‐PET) scan
Pretransplant 18F‐FDG uptake on PET scan in liver transplant candidates with HCC is a useful
additional parameter for the evaluation of tumor biology. Positive preoperative PET scans are
significantly associated with an increased risk of posttransplant HCC recurrence and inferior
outcome, an observation that relates a positive PET status with the presence of microvascular
invasion in explant tumor pathology [31]. In a recent Korean study, the combination of the
positive FDG‐PET study and AFP level >200 ng/ml could predict tumor recurrence more
precisely after LDLT than Milan criteria [35]. More recently, a retrospective study at our center
has showed that the combination of UCSF criteria with the FDG‐PET status can predict tumor
recurrence after LDLT and that tumor recurrence is earlier in cases with positive FDG‐PET
results. On the basis of the maximal standardized uptake value (SUVmax), high‐risk group
cases (positive study with SUVmax ≥ 5) had worse recurrence‐free survival compared with low‐
risk cases (positive study with SUVmax < 5) [53].
6.4. Donor characteristics
In addition to the previously discussed controversy of impact of donor type (living or de‐
ceased) on HCC recurrence, other donor factors have been studied. A recent review of the
American Scientific Registry of Transplant Recipients (SRTR) that involved 9724 patients
revealed that the following donor factors were independently associated with high risk of HCC
recurrence after transplantation: high BMI, history of DM, and severe graft steatosis. All the
previous factors are evident at the time of organ allocation and must be considered before
transplantation [54].
7. Loco‐regional therapy (LRT)
The pretransplant therapies are implemented heavily for HCC, being an essential component
of HCC treatment algorithms in most of treatment guidelines. Earlier in the treatment of HCC
roadmaps, they were considered “bridging” tools to keep the patient chances of LT during the
waiting time. Currently, a realized value of LRT is their ability to probe the tumor's internal
milieu, acting as a selecting tool based on the degree of tumor's response as an indicator of its
aggressiveness. So, adopting such therapies gives the time to observe the tumor's behavior
before the ultramajor costly step of liver transplantation [55]. Bypassing such an observation
period in the setting of multifocal or locally advanced tumor risks transplanting patients with
systemic disease.
7.1. HCC downstaging before liver transplantation
The difference between downstaging and neoadjuvant therapies is that in the former the tumor
status is beyond the proposed criteria for transplantation and LRT is administered to reduce
the tumor burden and to render the case fit for transplantation. In neoadjuvant therapy, the
patient is already within criteria but treatment is given to prevent tumor progression to the
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“beyond criteria” state while waiting for the donor and to induce tumor necrosis aiming at
better long‐term outcome [56].
In different series from Asian centers, more than 30% of patients who were beyond Milan/
UCSF criteria were effectively downstaged to the “within criteria” state with a 5‐year survival
rate similar to the initially fit cases [57, 58]. A meta‐analysis explored the effect of downstaging
to Milan criteria, and the success rate exceeded 40%. However, the recurrence rate was as high
as 16% [59].
TACE and RFA are the main tools of downstaging. TACE mediates its effect by inducing
complete pathological necrosis with response rates ranging between 27 and 57%. RFA is used
For accessible lesions to induce coagulative necrosis, either alone or in combination with liver
resection [60]. In LDLT, timing of transplantation after a period of waiting from the time of
LDLT is possible. Most centers wait for a period of 3–6 months to evaluate tumor progression
as an indicator of aggressiveness before embarking into LDLT.
Though widely applicable in most HCC guidelines, there are no unified criteria either for
selecting cases for downstaging or for determining them as good responders and hence listing
them for LT. This fact highlights the wide variation of transplantation criteria among different
regions and centers. As a rule of thumb, the criteria to enter a downstaging program should
include patients who have well‐defined and acceptable chances of good outcomes after
transplantation if the downstaging goal is achieved [56]. In our center, not only we apply
downstaging for cases beyond UCSF criteria, but also we consider cases with high AFP or high
FDG uptake on PET scan for downstaging. In our early experience, patients were downstaged
to fit Milan criteria. Our initial results of 35 patients were encouraging with a 5‐year survival
rate of 90% and those patients are still disease‐free up to date, after follow‐up of 10 years. Since
July 2006, our criteria were extended to UCSF criteria. In our experience of 161 HCC patients,
51 (31.6%) were successfully downstaged to fit the UCSF criteria. The overall 1‐ and 5‐year
survival rates for downstaged cases were 94.1 and 92.7%, respectively. The recurrence rate was
9.2%. The survival rates were similar for different pretransplantation downstaging proce‐
dures [57].
8. Operative/surgical highlights
The first successful case of liver transplantation in Asia was performed by Chen in 1984 in
Chang Gung Memorial Hospital, Taiwan. From the cumulative experience at our center, we
would like to emphasize that a sound surgical procedure is mandatory for the best outcome.
It has been postulated that the experience of the transplant team is an important factor that
independently affects the outcome though the learning curve of liver transplant can be steep
and painful in some centers launching an LDLT program. In essence, we prefer not to correct
recipient coagulopathy before surgery, because many studies showed no value of preoperative
correction. Donor hepatectomy should be accomplished with minimal blood loss, obviating
the need for blood transfusion. The routine use of microsurgical procedure is performed in
our center for arterial anastomosis as well as biliary reconstruction. Surgical outcome largely
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affects survival and hence final outcome. Early postoperative vascular complications are the
main reasons of graft loss and in‐hospital mortality and must be managed vigorously [49, 61–
64].
8.1. Timing of donor and recipient surgeries
In nonmalignant cases of LDLT, the recipient surgery is usually begun after the donor surgery
commenced till confirmation of feasible biliary anatomy by cholangiography. In the early
experience of LDLT for HCC, some surgeons preferred to confirm resectability of the liver
containing cancer and the absence of lymph node metastases through a smaller incision before
proceeding with graft harvesting from the donor [65, 66]. However, the current imaging
modalities surpass this step and allow precise decision in advance. Most experienced centers
largely depend on high quality CT or MRI images and the timing is adopted like nonmalignant
cases of end‐stage liver failure.
8.2. Safety margin
A proper safety margin is an integral part of the sound oncological surgical procedure. Some
peripheral lesions may be found in very close proximity to or even adherent to parietal
peritoneum, diaphragm, omentum, or less commonly small or large bowl loops. A previous
hepatectomy increases the adhesions with the aforementioned structures. It is thus convenient
to take a proper safety margin through excision of parts of peritoneum and diaphragmatic
muscle. Very infrequently, small or large bowl resection and anastomosis may be required. Re‐
exploration for additional safety margin after final pathological assessment is a very hazardous
procedure for such a frail patient, but may be warranted in some conditions according to
institutional experience.
8.3. Management of nodal disease
In a recent review from the International Registry of Hepatic Tumors in Liver Transplantation,
the incidence of lymph node metastases in cirrhotic patients with HCC undergoing LT was
6.5%. Hilar lymph node (LN) involvement in cases of HCC constitutes a contraindication for
liver transplantation because of dismal prognosis. Recent imaging techniques are able to
identify enlarged suspicious lymph nodes in the pretransplant setting. However, the frequent
presence of LN enlargement due to chronic inflammation in cases of hepatitis C‐induced
cirrhosis may make the diagnosis less clear. It is convenient to perform frozen section evalu‐
ation for suspicious nodes unexpectedly encountered during recipient operation. The decision
to proceed or abort the procedure in the case of inconclusive frozen section analysis or the
unavailability of frozen section depends largely on the experience of the transplant team.
According to a meta‐analysis study, systematic hilar lymphadenectomy during LT for HCC
should routinely be undertaken, especially in the context of coexisting hepatitis C or secondary
biliary cirrhosis. Some centers recommend harvesting of at least four lymph nodes at the time
of liver transplantation but the debate remains open with no available consensus on the extent
of such lymphadenectomy [67, 68].
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8.4. The middle hepatic vein (MHV)
The MHV is a controversial topic within the LDLT procedure in general. In the case of LDLT
for HCC, this issue should be taken more seriously. It has been postulated that the resultant
venous congestion from improper management of tributaries of MHV is a possible factor
favoring tumor recurrence. Congestion of the graft leads to impediment of portal inflow with
subsequent ischemia in the congested region and compensatory accelerated regeneration of
the well‐drained areas of the graft. Consequently, the cellular changes in response to both
processes may enhance tumor recurrence [69].
8.5. IVC management (see Figure 1)
The observation of HCC recurrence after LDLT in the hepatic vena‐caval wall has shed light
on the possibility of microvascular infiltration with consequent local and distant recurrence.
This finding triggered the concept of aggressive en‐bloc caval resection and reconstruction
during LDLT. This step is also justified by another two facts: first, it prevents a positive margin
of latent cancer in caval branches; second, the least amount of manipulation of the native liver
with HCC should be employed to avoid and control distant metastasis after LDLT [70].
Figure 1. A case of HCC subjected to LDLT. The tumor (T) was intimately adherent to the IVC wall without apparent
invasion in pretransplant CT angiography (A; arrow). During the recipient operation, the liver was explanted en‐bloc
with the IVC segment adjacent to the tumor. Reconstruction of the IVC was carried out using cryo‐preserved iliac v.
graft (B). Final gross pathology shows no intraluminal transgression by the tumor (C).
8.6. Complications of LDLT of the manipulated liver, i.e., after loco‐regional therapy
Extensive adhesions are commonly encountered following previous liver resection in case of
salvage liver transplantation. Tough vascular adhesions usually form between a large hepa‐
tectomy site and small intestine and omentum. Sharp dissection and meticulous hemostatic
control would reduce the difficulty of subsequent transplantation and decrease the incidence
of postoperative complications [71]. Laparoscopic liver resection is now performed on a wide
scale in many centers. One of the most prominent advantages of laparoscopic initial hepatec‐
tomy is the marked reduction of adhesions as evidenced in subsequent liver transplantation
in many series thus facilitating the procedure [72].
Intimal dissection (ID) of the recipient hepatic artery has emerged as a grave complication that
may occur after TAE or TACE. Intimal dissection if not discovered and managed properly may
end up in graft loss. Gentle handling of HA is mandatory during LT to prevent aggravation or
precipitation of dissection in the fragile HA. Once this complication is suspected intraopera‐
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tively, microscopic assessment is needed for proper decision. Either trimming and discarding
the dissected segment or discarding the whole native HA and reconstruction may be consid‐
ered, hence the importance of microvascular expertise in the LDLT team [73].
9. Ethical considerations
Two main ethical pillars of the decision of LDLT for management of HCC must be considered.
First, donor safety and optimizing his or her care is no different in LDLT for HCC compared
to that for nonmalignant cases of liver failure. Second, the procedure must provide an
acceptable outcome to the recipient compared to DDLT. From the ethical point of view, LDLT
is justified, as long as the proposed regional criteria are strictly followed, being MC or any
scientifically justified institutional expanded or modified criteria. Noteworthy that there is no
consensus about what risk to the living donor might be considered acceptable for a given risk
of recurrence [13, 74].
With increased awareness and patient education facilities, the ethical responsibilities regarding
patient counseling became more complex. It is not all about the perioperative complications.
Recently, ethical considerations took a very different perspective, that is offering LDLT to high‐
risk patients and excluding others who are low‐risk patients based on imaging criteria only.
As mentioned earlier, two wrongly estimated groups are revealed: cases within criteria that
have aggressive biological behavior and cases beyond criteria with indolent tumors. Two
ethical situations subsequently ensued; the first is the risk of recurrence of biologically
aggressive tumors even when strict criteria are adhered to, i.e., the underestimated group. The
second is about the loss of chance of LT in the other group. The transplantation team should
never rush to transplantation in response to family pressure and readily available donor
without proper discussion of all that issues [35].
When the partial graft fails for any reason, a special—but very uncommon—ethical situation
is encountered because normally it requires an urgent deceased donor retransplantation. It has
been established that if LDLT was used in a situation where a deceased donor is contraindi‐
cated, such as exceeding the accepted criteria for deceased donation, the patient should not be
retransplanted because he/she would not be transplanted initially if on wait‐list for DDLT [12,
66]. Finding another living donor must be balanced against the expected outcome of the
procedure. There are no clear‐cut decisions to such situations and the institutional experience
would tailor the right decision.
When talking about salvage LDLT, the patient may be reluctant to undergo the procedure even
with the availability of a donor. Some patients may argue that they want to be alive more but
do not want to harm anyone. In these circumstances, the transplant team should alert the
patient about how long can he/she delay the procedure without a considerable risk of tumor
progression or being transferred into the nontransplantable state. A study from Japan revealed
that patients who receive downstaging therapy can wait no more than 12 months. However,
the exact duration is not determined and the management plan should be tailored to each case
[75].
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10. Controversial topics
The increasing number of HCC cases, the parallel progress in expertise of LDLT, and the
dynamic changes in the selection criteria all enriched the liver transplantation community with
many important topics and debates. A lot of studies were carried out to find answers or to
reach a consensus in many of these topics. However, the retrospective nature of most studies,
the different reporting methodologies and small sample sizes are all flaws that hampered the
appearance of high level of evidence to address all topics.
10.1. What is the best treatment option of early HCC? Resection or liver transplantation?
Primary or salvage approach?
• The surgical decision can be either LR or LT in 20–25% of cases of HCC amenable for surgery.
Liver transplantation is hypothetically superior to resection because it removes the cancer
and its underlying pathology. For many patients it is not possible to perform resection
because of the tumor size, anatomical location of the tumor, or poor liver function, and liver
transplantation is the only surgical option [76]. However, even in many Asian centers which
perform LDLT on regular basis, up to 50% of early HCC cases may not have suitable donors
or be concerned about the risk to donor. So, many Asian centers adopt the policy of offering
LR to patients with resectable tumors with compensated cirrhosis and deferring LT to the
salvage setting [13, 23, 77, 78].
• The controversy regarding LR or LT in HCC patients is largely confined to early cases with
a well‐preserved liver function. There are no randomized controlled trials that addressed
this issue through a head‐to‐head comparison. Given that organ shortage for LT is a
persistent challenge worldwide and also the presence of underserved areas with deficient
LT programs, the identification of cases that would obtain similar survival outcomes when
either submitted to LR or to LT is of paramount importance [79, 80].
• The strategy of offering LR for simultaneously resectable and transplantable cases was based
on the observation from many studies that 20–30% of HCC cases that had LR may not
witness recurrence for >5 years. In addition, with vigilant surveillance programs, most of
recurrent cases would fit into the MC and can be transplanted under optimal conditions due
to the availability of the living donor, with no negative impact on the outcome. This obviates
many patients the downside of early immunosuppression [5]. In addition, the mortality rate
of LR at an experienced center is less than 2–5%, and overall survival rates were comparable
to primary LT [4, 24].
• The Barcelona Clinic Liver Cancer approach: Resection is the treatment of choice in patients
with very early stage HCC and normal bilirubin levels as well as the absence of portal
hypertension. If the liver functions are impaired, LT is recommended as a primary treatment
approach. In the early stage of HCC, it has been found that the 10‐year outcome after LT is
superior to LR in view of the latter's well‐known higher recurrence risk. So, the choice of
primary LT is recommended. The same approach is adopted by the American Association
of Study of Liver Disease (AASLD) guidelines that prefer liver resection for very early cases
with the optimal liver profile [7, 78, 81, 82].
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• A meta‐analysis of studies that involved patients within MC revealed a survival advantage
for LT over LR [83]. In a more recent meta‐analysis that involved 1572 patients in whom
both LR and LT are feasible, the authors did not find any survival advantage of LT compared
with LR. They concluded—based on low quality evidence—that LR is preferable to LT in
patients who are feasible for both options [84].
• Conclusion: the overall survival advantage of LT is unclear, though recurrence‐free survival
is definitely better with LT. The main drawback for LT—especially LDLT—is the relatively
increased mortality in the early postoperative period. In high volume centers where LDLT
is performed at high rates, perioperative mortality is reduced significantly. So, a clear overall
survival advantage for LT may be evident [85]. For a definite evidence‐based conclusion, a
randomized controlled trial comparing LT and LR is needed, a condition that is very difficult
due to practical and ethical restrictions. Proper patient selection and optimization of criteria
according to the pretransplant setting (primary or secondary) would help make a treatment
roadmap.
10.2. Living donor or deceased donor for HCC?
One of the most critical controversies in the transplantation field is the possibility of an
increased rate of recurrence of HCC after LDLT compared to DDLT.
Several hypotheses have been postulated to figure out this possibility:
• The fast tract effect: due to the shortened waiting time for LDLT, progression of HCC with
aggressive tumor biology might not be recognized during such a short‐waiting time. This
is in contrary to the situation in DDLT, where the long‐waiting time can naturally select cases
with indolent behavior.
• The growth factors and cytokines released during rapid regeneration of the partial grafts
might contribute to tumor progression and recurrence.
• The extensive dissection and mobilization of the liver might increase the feasibility of tumor
dissemination through the hepatic vein and increased potential for leaving residual tumor
cells.
• The exaggerated vascular inflow associated with small size grafts elicits vast angiogenesis
with subsequent carcinogenic effect.
• The less radical hepatectomy in LDLT with the native IVC left in place may constitute a
suboptimal oncologic procedure [15, 55, 86–88].
A multi‐center study was carried out on the database of China Liver Transplant Registry
(CLTR) to highlight this issue. They explored the data of 6860 patients (6471 (DDLT) and 389
LDLT and concluded that both overall survival and recurrence‐free survival were comparable
between both approaches [89]. In an international consensus conference of liver transplanta‐
tion (Zurich 2012), it had been stated that no convincing difference in outcome could be
identified according to the type of graft, although a higher risk of recurrence was noted in fast‐
tracked patients. The experts advised an interval of observation for the biological behavior of
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the tumor to manifest. A period of 3 months had been suggested [12]. Many other groups
reported similar recurrence rates after LDLT and DDLT and also similar long‐term outcomes
[14, 87].
However, others have found significantly higher rates of tumor recurrence after LDLT
compared with DDLT for HCC. The Adult to Adult Living Donor Liver transplantation
(A2ALL) study reported a significantly higher 3‐year tumor recurrence rate after LDLT [15,
88, 90, 91]. One should consider that many studies that reported better outcome of DDLT than
LDLT are conducted in the west and some of them were flawed by small sample sizes and the
possibility of selection bias since DDLT was applied mostly on cases within Milan criteria only
and those beyond Milan criteria are relegated to LDLT [92].
A systematic review and meta‐analysis addressed this question (Is the regenerating liver of
LDLT a fertile environment for HCC recurrence?). Though no randomized controlled trials
were included, they came to a similar conclusion; disease‐free survival (DFS) is worse after
LDLT compared with DDLT but there was no difference observed in overall survival (OS). In
the same meta‐analysis, there was a concern that the follow‐up periods in the included studies
are probably too brief to detect a major impact on survival resulting from differences in disease
recurrence. The same study revealed that the overall survival after LDLT vs. DDLT was better
—though not statistically significant—in studies from eastern centers compared with studies
from western centers. This may reflect differences between these regions in patient selection
or case‐volumes effects on surgical outcomes [6]. In conclusion, to date there is no definite
evidence supporting higher recurrence after LDLT than DDLT [55, 92].
10.3. Pre‐LDLT liver biopsy, can the trend be changed?
Because the risk of tumor seeding may be 2–4% along the needle biopsy tract and thus
increasing the risk of metastases, liver biopsy should be considered only when there is
uncertainty as to the diagnosis. This might occur, for example, in the presence of an HCC
arising in the noncirrhotic liver or contradictory clinical, laboratory, and radiological findings
[81]. However, a biopsy has the potential problems of sampling error. For example, different
nodules may have different grades within the index tumor. It has also been demonstrated that
even in a single‐needle biopsy, adjacent tumor cells can be of different degrees of differentia‐
tion. Nevertheless, if transplantation is planned for HCC beyond the standard criteria, tumor
biopsy appears to be a logical approach if there is suspicion of diagnosis [28].
Dubay et al. [44] have provided their experience in the University of Toronto based solely on
a liver biopsy before LT. They have no size or number restriction for LT. They concluded that
a protocol using a biopsy to exclude poorly differentiated tumors achieved excellent survival
rates (70% at 5 years) [44].
10.4. Can we exclude morphological selection criteria in the coming era?
Morphological criteria of HCC describe the appearance, while biological criteria describe the
concealed behavior. Ultimately, the behavior of HCC is the final‐deciding factor on patient
outcome. As shown earlier, modification of morphological criteria is pursued in many studies
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with the incorporation of biological factors [13]. In a study from Korea, the recipient selection
based on pure biological factors was proposed. The group showed that FDG PET positivity
with a cutoff point of maximum systemic uptake value (SUVmax) of 1.1 combined with the AFP
serum level at 400 ng/ml is able—alone—to predict patient outcome more precise than
morphological criteria [35]. More studies are needed to explore nonmorphological selection
processes.
11. Conclusions
LDLT is a robust treatment pathway for HCC. Indeed, it may be the only pathway in this era
of organ shortage especially in some Asian countries. The employment and dynamic applica‐
tion of selection criteria of LDLT for HCC are the cornerstone to acquire the best outcome. The
number and size of the tumor(s) are not the only factors to consider for patient selection but
some other factors are also present. Most of transplantation centers are combining biological
(AFP‐tumor avidity in PET scan) and pathological (pretransplant biopsy) factors of the tumors
to the morphological factors aiming at refined patient selection for the optimal outcome. In the
current era of personalized medicine, treatment of HCC should be tailored according to each
individual patient and tumor criteria. A sound oncological surgical procedure is the core of
successful LDLT and has its direct impact on the final outcome.
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